HUP0303987A2 - Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékok - Google Patents
Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékokInfo
- Publication number
- HUP0303987A2 HUP0303987A2 HU0303987A HUP0303987A HUP0303987A2 HU P0303987 A2 HUP0303987 A2 HU P0303987A2 HU 0303987 A HU0303987 A HU 0303987A HU P0303987 A HUP0303987 A HU P0303987A HU P0303987 A2 HUP0303987 A2 HU P0303987A2
- Authority
- HU
- Hungary
- Prior art keywords
- peptide ligand
- peptide
- ligand according
- labeler
- radioactive
- Prior art date
Links
- 229910052713 technetium Inorganic materials 0.000 title abstract 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical class C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 230000002285 radioactive effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000003446 ligand Substances 0.000 abstract 5
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000009920 chelation Effects 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052702 rhenium Inorganic materials 0.000 abstract 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 abstract 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
A találmány tárgyát képezi szomatosztatinreceptorhoz kötődőpeptidligand, amely természetben előforduló vagy természetben elő nemforduló aminosavakat vagy - N, C vagy mindkét terminálison módosított- peptidet utánozó szerkezetet, legalább egy szénhidrátot és legalábbegy kelátképző vagy prosztetikus csoportot tartalmaz, amellyeltechnécium vagy rénium radioizotópok komplexet képezhetnek. Atalálmány szerinti peptidligand adott esetben legalább egymultifunkcionális kapcsoló egységet is tartalmaz, amely adott esetbenösszeköti a peptidet és/vagy a cukoregységet és/vagy a kelátképzőtés/vagy a prosztetikus csoportot. A találmány tárgyát képezi továbbá atalálmány szerinti peptidligandot tartalmazó gyógyászati készítmény éseljárás a találmány szerinti peptidligand sst-leképezésben történőalkalmazására. A találmány szerinti peptidligand nukleárisgyógyászatban diagnosztikai és gyógyászati céllal alkalmazható. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201466 | 2001-04-23 | ||
| PCT/US2002/012565 WO2002085418A2 (en) | 2001-04-23 | 2002-04-23 | Tc and re labeler radioactive glycosylated octreotide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0303987A2 true HUP0303987A2 (hu) | 2004-03-01 |
| HUP0303987A3 HUP0303987A3 (en) | 2010-03-29 |
| HU228811B1 HU228811B1 (hu) | 2013-05-28 |
Family
ID=8180193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303987A HU228811B1 (hu) | 2001-04-23 | 2002-04-23 | Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékok |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7589061B2 (hu) |
| EP (1) | EP1381396B1 (hu) |
| JP (3) | JP5398945B2 (hu) |
| AT (1) | ATE427125T1 (hu) |
| AU (1) | AU2002254691B8 (hu) |
| BR (1) | BR0209074A (hu) |
| CA (1) | CA2443273C (hu) |
| CZ (1) | CZ20032872A3 (hu) |
| DE (1) | DE60231801D1 (hu) |
| HU (1) | HU228811B1 (hu) |
| WO (1) | WO2002085418A2 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7956165B2 (en) | 2003-07-24 | 2011-06-07 | Affisink Biotechnology Ltd. | Compositions and methods for purifying and crystallizing molecules of interest |
| IL157086A0 (en) * | 2003-07-24 | 2004-02-08 | Guy Patchornik | Multivalent ligand complexes |
| CN102253174A (zh) * | 2011-04-27 | 2011-11-23 | 江苏省原子医学研究所 | 一种受体显像剂标记的化学动力学研究的方法 |
| WO2013032011A1 (ja) * | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
| SG10201601327RA (en) * | 2011-09-04 | 2016-03-30 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
| CN106573959B (zh) * | 2014-06-06 | 2022-03-25 | 慕尼黑工业大学 | 修饰的环五肽及其用途 |
| DK3568205T3 (da) | 2017-01-12 | 2023-10-09 | Radiomedix Inc | Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194729C (nl) | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| JP2544159B2 (ja) | 1987-10-07 | 1996-10-16 | ハウス食品株式会社 | 連続蒸煮装置 |
| MY106120A (en) * | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
| US5590656A (en) * | 1992-09-15 | 1997-01-07 | The Ohio State University Research Foundation | Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue |
| US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| EP1486509A3 (en) | 1994-12-07 | 2005-03-23 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| CA2206274C (en) | 1994-12-07 | 2009-06-30 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| US5753206A (en) * | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| CA2241051A1 (en) | 1995-12-21 | 1997-10-23 | The Scripps Research Institute | Targeted therapeutic or diagnostic agents and methods of making and using same |
| DE19654764A1 (de) | 1996-12-30 | 1998-07-02 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung eines Peptidgemisches |
| JP4487019B2 (ja) | 1998-03-31 | 2010-06-23 | ランサス メディカル イメージング インコーポレイテッド | 血管新生疾患を画像化するための薬剤 |
| DE19910419A1 (de) | 1999-03-10 | 2000-09-21 | Aventis Pharma Gmbh | Zielzellspezifische, multivalente Proteine (MVP) |
-
2002
- 2002-04-23 AU AU2002254691A patent/AU2002254691B8/en not_active Ceased
- 2002-04-23 WO PCT/US2002/012565 patent/WO2002085418A2/en active IP Right Grant
- 2002-04-23 DE DE60231801T patent/DE60231801D1/de not_active Expired - Lifetime
- 2002-04-23 CA CA2443273A patent/CA2443273C/en not_active Expired - Fee Related
- 2002-04-23 US US10/475,696 patent/US7589061B2/en not_active Expired - Fee Related
- 2002-04-23 HU HU0303987A patent/HU228811B1/hu not_active IP Right Cessation
- 2002-04-23 JP JP2002582991A patent/JP5398945B2/ja not_active Expired - Fee Related
- 2002-04-23 BR BR0209074-0A patent/BR0209074A/pt not_active IP Right Cessation
- 2002-04-23 CZ CZ20032872A patent/CZ20032872A3/cs unknown
- 2002-04-23 EP EP02723932A patent/EP1381396B1/en not_active Expired - Lifetime
- 2002-04-23 AT AT02723932T patent/ATE427125T1/de not_active IP Right Cessation
-
2009
- 2009-09-10 US US12/556,698 patent/US8575100B2/en not_active Expired - Fee Related
- 2009-09-30 JP JP2009228998A patent/JP2010001313A/ja not_active Withdrawn
-
2013
- 2013-02-08 JP JP2013023001A patent/JP2013100349A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209074A (pt) | 2004-08-10 |
| HU228811B1 (hu) | 2013-05-28 |
| JP2005514321A (ja) | 2005-05-19 |
| JP5398945B2 (ja) | 2014-01-29 |
| HUP0303987A3 (en) | 2010-03-29 |
| US8575100B2 (en) | 2013-11-05 |
| WO2002085418A3 (en) | 2003-09-12 |
| US20060165593A1 (en) | 2006-07-27 |
| AU2002254691B8 (en) | 2008-02-14 |
| WO2002085418A2 (en) | 2002-10-31 |
| US7589061B2 (en) | 2009-09-15 |
| US20090324497A1 (en) | 2009-12-31 |
| CA2443273A1 (en) | 2002-10-31 |
| DE60231801D1 (de) | 2009-05-14 |
| JP2010001313A (ja) | 2010-01-07 |
| CA2443273C (en) | 2011-09-27 |
| ATE427125T1 (de) | 2009-04-15 |
| EP1381396B1 (en) | 2009-04-01 |
| EP1381396A2 (en) | 2004-01-21 |
| AU2002254691B2 (en) | 2007-06-14 |
| CZ20032872A3 (cs) | 2005-01-12 |
| JP2013100349A (ja) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reich et al. | Chair-side generated posterior lithium disilicate crowns after 4 years | |
| Marchack et al. | Customization of milled zirconia copings for all-ceramic crowns: a clinical report | |
| Culp et al. | Lithium disilicate: the restorative material of multiple options. | |
| Smales et al. | Long-term survival of porcelain laminate veneers using two preparation designs: a retrospective study. | |
| Mjör | Glass-ionomer cement restorations and secondary caries: a preliminary report. | |
| Bachhav et al. | Zirconia-based fixed partial dentures: a clinical review. | |
| Mangani et al. | Clinical approach to anterior adhesive restorations using resin composite veneers. | |
| Nazari et al. | Fracture strength of three-unit implant supported fixed partial dentures with excessive crown height fabricated from different materials | |
| Helal et al. | Effects of long‐term simulated RPD clasp attachment/detachment on retention loss and wear for two clasp types and three abutment material surfaces | |
| IL95547A0 (en) | Diamine chelating compounds,methods for the preparation thereof and pharmaceutical and diagnostic compositions containing the same | |
| Selz et al. | Full-mouth rehabilitation with monolithic CAD/CAM-fabricated hybrid and all-ceramic materials: A case report and 3-year follow up. | |
| HUP0303987A2 (hu) | Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékok | |
| Magne et al. | Risk of onlay fracture during pre-cementation functional occlusal tapping | |
| Jones et al. | Microleakage and shear bond strength of resin and porcelain veneers bonded to cast alloys | |
| NO972849D0 (no) | Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes | |
| Qualtrough et al. | A 3-year clinical evaluation of a porcelain inlay system | |
| Nejatidanesh et al. | Effect of surface treatment on the retention of implant-supported zirconia restorations over short abutments | |
| Costa et al. | Influence of different metal restorations bonded with resin on fracture resistance of endodontically treated maxillary premolars | |
| Angelara et al. | Comparison of strength of milled and conventionally processed PMMA complete-arch implant-supported immediate interim fixed dental prostheses | |
| Rosenblum | Restorative and orthodontic treatment of an adolescent patient with Amelogenesis Imperfects | |
| Jurado et al. | Comparison of full and partial coverage crowns with CAD/CAM leucite reinforced ceramic blocks on fracture resistance and fractographic analysis | |
| Ghasemi et al. | Effect of type of luting agents on stress distribution in the bone surrounding implants supporting a three-unit fixed dental prosthesis: 3D finite element analysis | |
| Rinke | Anterior all-ceramic superstructures: chance or risk? | |
| Salem | Margin design for esthetic posterior metal ceramic crowns | |
| Donovan et al. | The role of all-ceramic crowns in contemporary restorative dentistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: MALLINCKRODT LLC, US Free format text: FORMER OWNER(S): MALLINCKRODT, INC., US |
|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): VARNAI ES TARSAI UEGYVEDI IRODA DR. HATHAZI VERA UEGYVED, HU Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU |
|
| FH92 | Termination of representative |
Representative=s name: VARNAI ES TARSAI UEGYVEDI IRODA DR. HATHAZI VE, HU |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |